Stockscreener 앱 받기
8.70
2.06%
0.176
전일 마감가:
$8.524
열려 있는:
$8.28
하루 거래량:
2,490
Relative Volume:
0.26
시가총액:
$417.11M
수익:
$27,600
순이익/손실:
$-36.04M
주가수익비율:
-10.92
EPS:
-0.7968
순현금흐름:
$-1.66M
1주 성능:
-2.74%
1개월 성능:
+25.18%
6개월 성능:
+150.00%
1년 성능:
+62.31%
1일 변동 폭
$8.28
$8.70
1주일 범위
$8.03
$9.14
52주 변동 폭
$2.76
$10.59
나노바이오틱스 Stock (NBTX) Company Profile
NBTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
8.70 | 410.98M | 27,600 | -36.04M | -1.66M | -0.7968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
나노바이오틱스 Stock (NBTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-28 | 개시 | Guggenheim | Buy |
| 2023-12-08 | 개시 | Leerink Partners | Outperform |
| 2021-01-06 | 개시 | Evercore ISI | Outperform |
나노바이오틱스 주식(NBTX)의 최신 뉴스
Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.2% – Here’s Why - Defense World
Nanobiotix (NASDAQ:NBTX) Stock Price Up 2.9% – Should You Buy? - Defense World
Guggenheim Reaffirms Their Buy Rating on Nanobiotix (NBTX) - The Globe and Mail
Nanobiotix (NASDAQ:NBTX) Stock Price Down 2.5% – Should You Sell? - Defense World
Nanobiotix announces regulatory harmonization, new patent for JNJ-1900 - TipRanks
Nanobiotix Sa ADR Reports Q1 2025 Progress - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast - GlobeNewswire Inc.
Guggenheim cuts Nanobiotix stock target to $8, maintains buy - Investing.com
Nanobiotix SA ADR Reports 2024 Financial Results - TipRanks
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study - Nasdaq
Nanobiotix announces FDA issuance of Study May Proceed Letter for NBTXR3 study - TipRanks
Nanobiotix (NBTX) Stock Soared 107.9% on a Global Pharma Deal - AskTraders.com
NBTX News Today | Why did Nanobiotix stock go up today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
나노바이오틱스 (NBTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):